hotspot -WSS

hotspot

author：comprehensive 2025-09-27 16:16:44 - browse：53836

How do cancer drugs work? What makes biotech stocks go up? And why are venture capitalists so optimistic?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Andrew Joseph joins us to explain the decades-old cancer-treating technology that had its star turn at this week’s big oncology conference in Europe. We also discuss the latest news in the life sciences, including the future of Alzheimer’s disease treatment, a multibillion-dollar deal, and the return of the biotech mega-round.

For more on what we cover, here’s STAT’s coverage of the European Society for Medical Oncology meeting; here’s more on Roivant Sciences; here’s the latest on biotech venture capital; here’s more on the latest Alzheimer’s data; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： States should stop sabotaging methadone treatment reform

WSS

UnitedHealth, Optum discontinue NaviHealth name

STAT Summit: Ending the crisis of Black deaths in the U.S.

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

Why the world’s most expensive drug might be worth the price

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

explore

hotspot

hotspot

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Merck, Vertex, and Viking updates

The high cost of giving birth even with insurance

Why the world’s most expensive drug might be worth the price

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

J&J lung cancer data amount to new salvo against AstraZeneca

Drug repurposing or repositioning? The language matters

Cassava Sciences’ Alzheimer’s clinical trials should be halted

How one medical school became remarkably diverse

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

focus

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Vertex Pharmaceuticals may move headquarters in Boston

Readout Newsletter: Merck, Vertex, and Viking updates

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Readout LOUD podcast: Live from the 2023 STAT Summit

Readout LOUD podcast: mifepristone case, GLP

entertainment

entertainment

focus

knowledge